Treatment Adherence Disparities and Clinical Outcomes of Osimertinib among Ethnic-Minority Patients with EGFR-Mutated NSCLC

被引：0
|
作者：
Lee, M. [1 ]
Miao, E. [2 ]
Zhang, C. [2 ]
Xue, X. [2 ]
Tuckman, S. [3 ]
Halmos, B. [1 ]
Cheng, H. [1 ]
机构：
[1] Montefiore Einstein Canc Ctr MECC, Bronx, NY USA
[2] Albert Einstein Coll Med, Bronx, NY 10467 USA
[3] Montefiore Med Ctr, Bronx, NY USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Osimertinib adherence; NSCLC; Socioeconomic healthcare; disparities;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.09-04
引用
收藏
页码：S331 / S332
页数：2
相关论文
共 50 条
  • [1] Treatment adherence and clinical outcomes of osimertinib (Osi) among ethnic-minority patients (pts) with EGFR-mutated NSCLC
    Lee, Matthew
    Miao, Emily
    Zhang, Chenxin
    Xue, Xiaonan
    Tuckman, Steven
    Halmos, Balazs
    Cheng, Haiying
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Socioeconomic Disparities and Overall Survival Differences Among Ethnic-Minority Patients with EGFR-Mutated NSCLC Treated with Osimertinib
    Lee, M.
    Miao, E.
    Zhang, C.
    Xue, X.
    Tuckman, S.
    Ohri, N.
    Halmos, B.
    Cheng, H.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S192 - S194
  • [3] Clinical outcomes in Black patients with EGFR-mutated NSCLC treated with osimertinib
    Belani, Neel
    Rizwan, Farsha
    Hasler, Jill
    Bauman, Jessica
    Mitchell, Khadijah
    Borghaei, Hossein
    Bodor, Joseph N.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2024, 33 (09)
  • [4] A Retrospective Comparison of Survival Outcomes in EGFR-mutated, NSCLC Patients on Osimertinib plus /- Brain Metastases
    Litt, I.
    Gibson, A.
    Dean, M.
    Elegbede, A.
    Bebb, G.
    Cheung, W.
    Pabani, A.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S232 - S232
  • [5] Treatment Strategies and Survival Outcomes of Patients with EGFR-mutated NSCLC and leptomeningeal metastasis
    Fan, Y.
    Wu, H.
    Chen, K.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S652 - S652
  • [6] Prognostic impact of bone metastases in osimertinib-treated patients with EGFR-mutated NSCLC
    Tanaka, Ichidai
    Gen, Soei
    Hori, Kazumi
    Morise, Masahiro
    Koyama, Junji
    Kodama, Yuta
    Matsui, Akira
    Miyazawa, Ayako
    Hase, Tetsunari
    Hibino, Yoshitaka
    Yokoyama, Toshihiko
    Kimura, Tomoki
    Yoshida, Norio
    Sato, Mitsuo
    Ishii, Makoto
    CANCER SCIENCE, 2025, 116 : 329 - 329
  • [7] Clinical analysis of the presence of comutations in patients with EGFR-mutated NSCLC
    Rubio, Jaime
    Santolaya, Carlota
    Fernandez, Marina
    Villalba, Paula Lucia
    Avedillo, Mercedes
    Garcia-Foncillas, Jesus
    Domine, Manuel
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy
    Hayashi, Hidetoshi
    Nishio, Makoto
    Takahashi, Michiko
    Tsuchiya, Hiroaki
    Kasahara-Kiritani, Mami
    ADVANCES IN THERAPY, 2023, 40 (10) : 4545 - 4560
  • [9] Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy
    Hidetoshi Hayashi
    Makoto Nishio
    Michiko Takahashi
    Hiroaki Tsuchiya
    Mami Kasahara-Kiritani
    Advances in Therapy, 2023, 40 : 4545 - 4560
  • [10] Mortality among EGFR-mutated advanced NSCLC patients after frontline osimertinib treatment: A real-world, US attrition analysis
    Girard, N.
    Leighl, N.
    Ohe, Y.
    Kim, T. M.
    Demirdjian, L.
    Bourla, A. B.
    Sultan, A. Abdul
    Mahadevia, P.
    Bauml, J. M.
    Sabari, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S51 - S52
12345